Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis –

– Initiated Phase 1 clinical trial for A-005 in healthy participants –